Radium-223 for the treatment of castration-resistant prostate cancer.

about

Treatment of Metastatic Prostate Cancer in Older Adults.Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?

P2860

Q38944255-E5A0D8B9-25E9-4695-A922-369AA60D06BF Q58759090-4408B4E6-D9BB-40BC-B844-BAF48E49EBA7

P2860

Radium-223 for the treatment of castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q35653986

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Radium-223 for the treatment of castration-resistant prostate cancer.

@ast

Radium-223 for the treatment of castration-resistant prostate cancer.

@en

type

Item

label

Radium-223 for the treatment of castration-resistant prostate cancer.

@ast

Radium-223 for the treatment of castration-resistant prostate cancer.

@en

prefLabel

Radium-223 for the treatment of castration-resistant prostate cancer.

@ast

Radium-223 for the treatment of castration-resistant prostate cancer.

@en

P1476

Radium-223 for the treatment of castration-resistant prostate cancer

@en

P2093

Joelle El-Amm

http://www.w3.org/2001/XMLSchema#string

P2860

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

Alpha emitter radium-223 and survival in metastatic prostate cancer

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 A

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

P304

1103-1109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S44291

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeanny B Aragon-Ching

P577

2015-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26056474

http://www.w3.org/2001/XMLSchema#string

P932

4445785

http://www.w3.org/2001/XMLSchema#string

Radium-223 for the treatment of castration-resistant prostate cancer.

about

P2860

P2860

Radium-223 for the treatment of castration-resistant prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932